These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11297242)

  • 1. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
    Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
    Furuhata T; Meguro M; Nishidate T; Okita K; Ishiyama G; Iwayama Y; Hosokawa Y; Tsuruma T; Kimura Y; Mizuguchi T; Sasaki K
    Int J Clin Oncol; 2009 Dec; 14(6):529-33. PubMed ID: 19967490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
    Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
    Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
    Etienne-Grimaldi MC; François E; Cardot JM; Renée N; Douillard JY; Gamelin E; Bennouna J; Château Y; Milano G
    Clin Pharmacokinet; 2007; 46(11):953-63. PubMed ID: 17922560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Noel D; Sonnichsen DS; Birkhofer MJ
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):22-5. PubMed ID: 9348562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
    Meropol NJ; Rustum YM; Petrelli NJ; Rodriguez-Bigas M; Frank C; Ho DH; Kurowski M; Creaven PJ
    Cancer Chemother Pharmacol; 1996; 37(6):581-6. PubMed ID: 8612313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
    J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Hoff PM; Lassere Y; Pazdur R
    Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
    Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
    Urien S; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Deporte-Fety R
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):99-107. PubMed ID: 12768319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.